# US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings

Source: https://welltoldgrants.com/grants/rfa-ip-22-004-us-platform-to-measure-effectiveness-of-seasonal-influenza/  
Official notice: https://www.grants.gov/search-results-detail/334859

> Centers for Disease Control and Prevention - ERA offered grants of up to $9.1 million (at least $2.0 million) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 8 awards worth $108 million in total. Applications closed on May 9, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-IP-22-004 |
| Agency | Centers for Disease Control and Prevention - ERA |
| Status | Forecast |
| Deadline | May 9, 2022 |
| Award ceiling | $9.1 million |
| Award floor | $2.0 million |
| Expected awards | 8 |
| Total funding | $108 million |
| Cost sharing | not required |
| Assistance Listings | 93.083, 93.185 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

N/A

## What the grant funds

Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.

## Questions people ask

### Is RFA-IP-22-004 still open?

No. It closed on May 9, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.

### Who can apply for US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings?

Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings?

Closed May 9, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $9.1 million each. About $108 million in total across about 8 awards.

### Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before?

The largest recipients over five fiscal years were Council of Medical Specia, Post-Acute and Long-Term Care Medical Association, Inc., National Health Laboratory Service. The program made 30 awards worth $58.2 million in that time.